Recent developments in recombinant AAV-mediated gene therapy for lung diseases

Area of Science:

• * Gene Therapy
• * Molecular Virology
• * Respiratory Medicine

Background:

• * Recombinant adeno-associated virus (AAV) vectors are promising for respiratory gene therapy.
• * Significant obstacles hinder safe and effective gene transfer to the respiratory tract.
• * These include vector entry, nuclear transport, genome conversion, and immune responses.

Purpose of the Study:

• * To review and highlight advancements in overcoming barriers to AAV-mediated respiratory gene transfer.
• * To discuss novel vector designs and emerging AAV serotypes for improved gene therapy outcomes.

Main Methods:

• * Review of recent scientific literature on AAV vector technology and respiratory gene therapy.
• * Analysis of challenges in AAV vector delivery, transduction, and persistence in the respiratory tract.
• * Examination of innovative strategies and new AAV serotypes developed to address these challenges.

Main Results:

• * New vector designs have been developed to circumvent issues like receptor binding, internalization, and proteasomal degradation.
• * Strategies to improve nuclear entry and episomal genome conversion have been investigated.
• * Advances in vector design and the discovery of novel AAV serotypes offer enhanced tropism and reduced immunogenicity.

Conclusions:

• * Significant progress has been made in addressing key obstacles to AAV gene transfer in the respiratory tract.
• * Novel vector designs and a wider array of AAV serotypes are expanding therapeutic possibilities.
• * These advancements pave the way for more effective and safer long-term gene therapy for respiratory diseases.